Navigation Links
Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008

Zevalin(R) on Track for Break-Even in 2008

SEATTLE, Nov. 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported financial results for the quarter ended September 30, 2008. Total revenues for the quarter were $2.6 million compared to $20,000 for the third quarter of 2007 due primarily to sales of Zevalin(R) (Ibritumomab Tiuxetan), a commercial radiopharmaceutical that CTI acquired in December 2007. Net product sales of Zevalin totaled $2.6 million in the third quarter of 2008. The Company also reported a significant decrease in operating expenses compared to the same period in 2007.

"We continue to make significant progress on the commercial front with the submission for a label expansion of Zevalin in September and our plan to report top-line results from the pixantrone pivotal trial in November, which if positive, would lead to us submitting an NDA in 2009," said James A. Bianco, M.D., CEO of CTI. "Importantly, we have made this progress while keeping in line with our strategy of reducing our expenses. Our net cash used for operating activities in the third quarter averaged approximately $5.75 million per month, a decrease of 27% from last quarter, and we are on target to reach our goal of $4.5 million per month in ongoing operating expenses in 2009."

Recent Highlights

-- Submitted supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) in September for use of Zevalin as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma based on First-line Indolent Trial data.

-- Announced that CTI has closed the data set for preliminary analysis of the primary endpoint in the phase III EXTEND (PIX301) trial of pixantrone (BBR2778) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL) and anticipates reporting top-line results in November.

-- Announced that Christina Waters, Ph.D. most recently President and COO of Tyr Pharma and formerly Director of Scientific Development at Genomics Institute of the Novartis Research Foundation, has been named President of CTI Europe and CTI's Systems Medicine subsidiary.

Total operating expenses decreased $28.5 million, or 58 percent, to $20.5 million for the quarter ended September 30, 2008 compared to $49.0 million for the same period in 2007 mainly as a result of decreased research and development expenses in the third quarter of 2008 and a one-time non-cash charge for the acquisition of Systems Medicine recorded in the third quarter of 2007. Research and development costs decreased $7.2 million, or 39 percent, to $11.3 million for the current quarter compared to $18.6 million for the same period in 2007 as the result of our cost reduction initiatives and expenses related to our clinical trial programs. Net loss attributable to common shareholders decreased to $47.6 million ($2.83 per share) for the quarter ended September 30, 2008, compared to $52.6 million ($10.91 per share) for the comparable period in 2007.

The Company had approximately $11.7 million in cash and cash equivalents, securities available-for-sale, and interest receivable as of September 30, 2008. This does not include $29.4 million in restricted cash held in escrow for future make-whole and interest payments on our 9%, 15%, 15.5% and 18.33% convertible senior notes. It also does not include net proceeds, before fees and expenses, of approximately $7.5 million from the purchase of 9.66% Convertible Senior Notes due 2011 by a single investor in October 2008. Even with this additional financing, the Company will need to raise additional capital this year and is exploring alternatives to do so, which may include potential partnerships or joint ventures, public or private equity financings, debt financings or restructurings, dispositions of assets or through other means in order to fund its continued operations.

Conference Call Information

On Friday, November 7, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a quarterly conference call to discuss the Company's 2008 third quarter achievements and financial results.

Conference Call Numbers

Friday, November 7

8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time

1-877-835-3299 (US Participants)

1-303-262-2078 (International)

Call-back numbers for post-listening available at 11:30 a.m. Eastern:

1-800-405-2236 (US Participants)

1-303-590-3000 (International)

Passcode: 11121525#

Live audio webcast at will be archived for post listening approximately two hours after call ends.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

This press release includes forward-looking statements about our commercial progress, potential regulatory filings, expected timing of clinical trial results as well as efforts to reduce operating expenses, that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include statements about future sales of Zevalin, including the risk that the data from the FIT trial may not prove adequate to support an approval of an sBLA for label expansion of that product, the preliminary results we expect to report on our phase III pivotal trial of pixantrone later this month may not be positive, our ability to continue to reduce our operating expenses, the Company's ability to continue to raise capital as needed to fund its operations, the outcome of our pending hearing before a Nasdaq Listing Qualifications Panel as a result of our continued non-compliance with Nasdaq's quantitative requirements to remain listed, the development of OPAXIO, pixantrone, and brostallicin, which include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with OPAXIO, pixantrone, and brostallicin in particular, including, without limitation, the potential failure of these product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, OPAXIO, pixantrone, and brostallicin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

F: 206.272.4434


Investors Contact:

Ed Bell

T: 206.282.7100

Lindsey Jesch Logan

T: 206.272.4347

F: 206.272.4434


Cell Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except for per share amounts)


Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007


Product sales $2,580 $- $8,824 $-

License and contract revenue 20 20 60 60

Total revenues 2,600 20 8,884 60

Operating expenses:

Cost of product sold 692 - 2,349 -

Research and development 11,326 18,566 43,038 50,368

Selling, general and

administrative 7,834 8,874 30,526 24,594

Amortization of purchased

intangibles 606 219 1,540 638

Acquired in-process research

and development - 21,343 36 21,343

Total operating expenses 20,458 49,002 77,489 96,943

Loss from operations (17,858) (48,982) (68,605) (96,883)

Other income (expense):

Investment and other income, net 146 626 499 2,067

Interest expense (2,575) (2,127) (6,955) (6,146)

Amortization of debt discount

and issuance costs (11,113) (336) (52,259) (3,911)

Foreign exchange gain 3,070 2,308 909 3,142

Make-whole interest expense (19,135) - (52,512) (2,310)

Gain on derivative

liabilities, net 12,915 4 56,092 3,618

Loss on exchange of

convertible notes (10,272) - (15,880) -

Write-off of financing

arrangement costs - - (2,361) -

Settlement expense (799) - (799) (160)

Loss before minority interest (45,621) (48,507) (141,871) (100,583)

Minority interest in net loss

of subsidiary 32 36 95 36

Net loss (45,589) (48,471) (141,776) (100,547)

Preferred stock beneficial

conversion feature - (3,918) (1,067) (8,301)

Preferred stock dividends (106) (214) (574) (395)

Deemed dividends on conversion

of preferred stock (1,951) - (18,149) -

Net loss attributable to common

shareholders $(47,646) $(52,603) $(161,566) $(109,243)

Basic and diluted net loss per

common share $(2.83) $(10.91) $(13.68) $(25.48)

Shares used in calculation of

basic and diluted net loss per

common share (1) 16,812 4,820 11,807 4,287

Balance Sheet Data: (amounts in thousands)

September 30, December 31,

2008 2007

Cash and cash equivalents, securities (unaudited)

available-for-sale and interest receivable $11,739 $18,392

Restricted cash 29,441 -

Working capital 7,625 (30,909)

Total assets 93,746 73,513

Convertible debt 169,463 137,396

Accumulated deficit (1,270,979) (1,109,413)

Shareholders' deficit (133,380) (134,125)

(1) Amounts reflect a one-for-ten reverse stock split of our common stock

effective August 31, 2008.

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. CV Therapeutics Reports 2008 Third Quarter Financial Results
4. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
5. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
6. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
7. Nile Therapeutics to Present at Two Upcoming Investor Conferences
8. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
9. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
10. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
11. United Therapeutics Reports Third Quarter 2008 Financial Results
Post Your Comments:
(Date:11/27/2015)... 2015 --> ... companion diagnostics is one of the major ... pharmaceutical companies and diagnostic manufacturers working together ... . --> ... global cancer biomarkers market spread across 89 ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
(Date:10/27/2015)... Germany , October 27, 2015 ... SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically maps ... SMI,s Eye Tracking Glasses , so that they ... BeGaze. --> Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ...
Breaking Biology News(10 mins):